Operating Lease, Right-of-Use Asset of Akero Therapeutics, Inc. from 01 Jan 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Akero Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 01 Jan 2020 to 30 Sep 2025.
  • Akero Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $552,000, a 33% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Akero Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $552,000 -$268,000 -33% 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $621,000 -$263,000 -30% 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $689,000 -$257,000 -27% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $755,000 -$253,000 -25% 31 Dec 2024 10-Q 07 Nov 2025 2025 Q3
Q3 2024 $820,000 -$248,000 -23% 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $884,000 -$243,000 -22% 30 Jun 2024 10-Q 09 Aug 2024 2024 Q2
Q1 2024 $946,000 -$239,000 -20% 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $1,008,000 -$234,000 -19% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $1,068,000 -$229,000 -18% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $1,127,000 -$225,000 -17% 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q1 2023 $1,185,000 -$221,000 -16% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $1,242,000 -$217,000 -15% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $1,297,000 -$214,000 -14% 30 Sep 2022 10-Q 04 Nov 2022 2022 Q3
Q2 2022 $1,352,000 -$210,000 -13% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $1,406,000 -$206,000 -13% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $1,459,000 -$203,000 -12% 31 Dec 2021 10-K 17 Mar 2023 2022 FY
Q3 2021 $1,511,000 -$199,000 -12% 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $1,562,000 30 Jun 2021 10-Q 13 Aug 2021 2021 Q2
Q1 2021 $1,612,000 +$1,386,000 +613% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $1,662,000 +$1,382,000 +494% 31 Dec 2020 10-K 25 Feb 2022 2021 FY
Q3 2020 $1,710,000 30 Sep 2020 10-Q 12 Nov 2020 2020 Q3
Q1 2020 $226,000 31 Mar 2020 10-Q 13 May 2020 2020 Q1
Q4 2019 $280,000 01 Jan 2020 10-K 16 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.